EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden

Hyungtai Sim iD, Hyun Jung Park, Geun-Ho Park, Yeon Jeong Kim, Woong-Yang Park, Se-Hoon Lee, Murim Choi iD

eLife · 06.12.2024 · 13

DOI: 10.7554/elife.96951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 06.12.2024. Verfasst von Hyungtai Sim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Clonal Hematopoiesis, Myeloid Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute, Samsung Medical Center, Sungkyunkwan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal hematopoiesis of indeterminate potential (CHIP) allows estimation of clonal dynamics and documentation of somatic mutations in the hematopoietic system. Recent studies utilizing large cohorts of the general population and patients have revealed significant associations of CHIP burden with age and disease status, including in cancer and chronic diseases. An increasing number of cancer patients are treated with immune checkpoint inhibitors (ICIs), but the association of ICI response in non-small cell lung cancer (NSCLC) patients with CHIP burden remains to be determined. We collected blood samples from 100 metastatic NSCLC patients before and after ICI for high-depth sequencing of the CHIP panel and 63 samples for blood single-cell RNA sequencing. Whole exome sequencing was performed in an independent replication cohort of 180 patients. The impact of CHIP status on the immunotherapy response was not significant. However, metastatic lung cancer patients showed higher CHIP prevalence (44/100 for patients vs. 5/42 for controls; p = 0.01). In addition, lung squamous cell carcinoma (LUSC) patients showed increased burden of larger clones compared to lung adenocarcinoma (LUAD) patients (8/43 for LUSC vs. 2/50 for LUAD; p = 0.04). Furthermore, single-cell RNA-seq analysis of the matched patients showed significant enrichment of inflammatory pathways mediated by NF-κB in myeloid clusters of the severe CHIP group. Our findings suggest minimal involvement of CHIP mutation and clonal dynamics during immunotherapy but a possible role of CHIP as an indicator of immunologic response in NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsClonal HematopoiesisMyeloid CellsHumansFemaleMaleAgedMiddle AgedInflammationMutationImmune Checkpoint InhibitorsAged, 80 and overAdultSingle-Cell AnalysisExome Sequencing

Stichwörter der Autor:innen

NSCLCcancer biologyclonal hematopoiesishumanimmune checkpoint inhibitorinflammation

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea.
  • Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea.
  • Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea.

ORCID-Profile: Hyungtai Sim, Murim Choi

Förderung

  • National Research Foundation of Korea
  • Korea Health Industry Development Institute
  • Samsung Medical Center, Sungkyunkwan University

Zitieren

APA

Sim, H., Park, H. J., Park, G. H., Kim, Y. J., Park, W. Y., Lee, S. H., & Choi, M. (2024). Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden. eLife, 13. https://doi.org/10.7554/elife.96951

Vancouver

Sim H, Park HJ, Park GH, Kim YJ, Park WY, Lee SH, et al. Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden. eLife. 2024;13. doi:10.7554/elife.96951

BibTeX
@article{Sim2024,
  author = {Sim, Hyungtai and Park, Hyun Jung and Park, Geun-Ho and Kim, Yeon Jeong and Park, Woong-Yang and Lee, Se-Hoon and Choi, Murim},
  title = {Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden},
  journal = {eLife},
  year = {2024},
  volume = {13},
  doi = {10.7554/elife.96951}
}
Kostenlos starten →